Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Discovery and development of spleen tyrosine kinase (SYK) inhibitors.

× No keyword cloud information.

19 in total

Review 1. Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.

Authors: Eleanor M Pritchard; Michael A Dyer; R Kiplin Guy
Journal: Mini Rev Med Chem Date: 2016 Impact factor: 3.862

2. Pharmacological Inhibition of Spleen Tyrosine Kinase Suppressed Neuroinflammation and Cognitive Dysfunction in LPS-Induced Neurodegeneration Model.

Authors: Min Woo Kim; Kyonghwan Choe; Jun Sung Park; Hyeon Jin Lee; Min Hwa Kang; Riaz Ahmad; Myeong Ok Kim
Journal: Cells Date: 2022-05-28 Impact factor: 7.666

3. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma.

Authors: Eleanor M Pritchard; Elizabeth Stewart; Fangyi Zhu; Cori Bradley; Lyra Griffiths; Lei Yang; Praveen Kumar Suryadevara; Jiakun Zhang; Burgess B Freeman; R Kiplin Guy; Michael A Dyer
Journal: Pharm Res Date: 2014-06-07 Impact factor: 4.200

4. A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.

Authors: Ming Jiang; Renping Liu; Ying Chen; Qisheng Zheng; Saijun Fan; Peixun Liu
Journal: Int J Mol Sci Date: 2014-09-25 Impact factor: 5.923

5. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.

Authors: Michael G Rolf; Jon O Curwen; Margaret Veldman-Jones; Cath Eberlein; Jianyan Wang; Alex Harmer; Caroline J Hellawell; Martin Braddock
Journal: Pharmacol Res Perspect Date: 2015-09-04

6. A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.

Authors: Gregory D Ferguson; Mercedes Delgado; Veronique Plantevin-Krenitsky; Kristen Jensen-Pergakes; R J Bates; Sanaa Torres; Maria Celeridad; Heather Brown; Kelven Burnett; Lisa Nadolny; Lida Tehrani; Garrick Packard; Barbra Pagarigan; Jason Haelewyn; Trish Nguyen; Li Xu; Yang Tang; Matthew Hickman; Frans Baculi; Steven Pierce; Keiji Miyazawa; Pilgrim Jackson; Philip Chamberlain; Laurie LeBrun; Weilin Xie; Brydon Bennett; Kate Blease
Journal: PLoS One Date: 2016-01-12 Impact factor: 3.240

Review 7. Syk inhibitors in clinical development for hematological malignancies.

Authors: Delong Liu; Aleksandra Mamorska-Dyga
Journal: J Hematol Oncol Date: 2017-07-28 Impact factor: 17.388

Review 8. Syk Activity Is Dispensable for Platelet GP1b-IX-V Signaling.

Authors: Rachit Badolia; John C Kostyak; Carol Dangelmaier; Satya P Kunapuli
Journal: Int J Mol Sci Date: 2017-06-09 Impact factor: 5.923

9. Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL.

Authors: Dimitar G Efremov; Adrian Wiestner; Luca Laurenti
Journal: Mediterr J Hematol Infect Dis Date: 2012-10-09 Impact factor: 2.576

10. Crystal Structures of Spleen Tyrosine Kinase in Complex with Two Novel 4-Aminopyrido[4,3-d] Pyrimidine Derivative Inhibitors.

Authors: Sang Jae Lee; Jang-Sik Choi; Seoung Min Bong; Hae-Jun Hwang; Jaesang Lee; Ho-Juhn Song; Jaekyoo Lee; Jung-Ho Kim; Jong Sung Koh; Byung Il Lee
Journal: Mol Cells Date: 2018-06-12 Impact factor: 5.034